The 38th International Conference on Antiviral Research (ICAR), sponsored by the International Society for Antiviral Research (ISAR), took place March 17-21, 2025 in Las Vegas, Nevada, USA. The annual meeting brought together leading scientists from across academia, industry, and government to present the latest advances in antiviral research. Topics included discovery and development of novel antiviral agents, innovative therapeutic approaches, vaccine technologies, host-targeted strategies, and responses to emerging and re-emerging viral threats. ICAR 2025 featured keynote talks, short oral presentations, poster sessions and special sessions to encourage discussions between attendees and foster interdisciplinary collaboration. Several events were held to support the next generation of antiviral researchers, including dedicated sessions and networking opportunities focused on mentorship and career development for students, postdoctoral fellows, and early-career scientists. Importantly, ISAR continues to serve as a cornerstone for international collaboration and innovation in antiviral science, and the society is eager to continue these efforts at the 39th ICAR, to be held in Prague, Czech Republic, from April 27-May 1, 2026.

Baker Institute and Department of Microbiology and Immunology Cornell University Ithaca NY USA

Baruch S Blumberg Institute Doylestown PA USA; School of Pharmacy University of Michigan Ann Arbor MI USA; Ernest Mario School of Pharmacy Rutgers University Piscataway NJ USA

Bill and Melinda Gates Foundation Seattle WA USA

Centre International de Recherche en Infectiologie Inserm_U1111 CNRS_UMR5308 Université Claude Bernard Lyon 1 F 69007 Lyon France

Department of Chemistry and Biochemistry University of Maryland Baltimore County Baltimore MD USA

Department of Epidemiology University of North Carolina at Chapel Hill Chapel Hill NC USA; Department of Microbiology and Immunology University of North Carolina School of Medicine Chapel Hill NC USA; Rapidly Emerging Antiviral Drug Development Initiative University of North Carolina at Chapel Hill Chapel Hill NC USA

Department of Microbiology and Immunology Cancer Virology Program UPMC Hillman Cancer Center University of Pittsburgh School of Medicine Pittsburgh PA USA

Department of Microbiology and Immunology SUNY Upstate Medical University Syracuse NY USA

Department of Microbiology and Immunology University of Texas Medical Branch Galveston TX USA; Sealy Institute for Drug Discovery University of Texas Medical Branch Galveston TX USA

Division of the Laboratory of Biochemical Pharmacology Department of Pediatrics Emory University School of Medicine Children's Healthcare of Atlanta Atlanta GA USA

Institute for Biomedicine and Glycomics Griffith University Southport QLD Australia

Institute of Microbiology University Hospital of Lausanne University of Lausanne 1011 Lausanne Switzerland

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nám 2 160 00 Prague Czech Republic

KU Leuven Department of Microbiology Immunology and Transplantation Rega Institute Laboratory of Virology and Antiviral Research Leuven Belgium

KU Leuven Department of Microbiology Immunology and Transplantation Rega Institute Laboratory of Virus Host Interactions and Therapeutic Approaches Research Group Leuven Belgium

Laboratory of Antiviral Drug Discovery Institute of Molecular Biology of National Academy of Sciences 0014 Yerevan Armenia; Denovo Sciences Inc 0060 Yerevan Armenia

University of North Carolina HIV Cure Center USA; Division of Infectious Diseases Department of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA

Viral Special Pathogens Branch Division of High Consequence Pathogens and Pathology Centers for Disease Control and Prevention Atlanta GA USA

Zobrazit více v PubMed

Adam A, Kalveram B, Chen JY-C, Yeung J, Rodriguez L, Singh A, Shi P-Y, Xie X, Wang T, 2023. A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity. NPJ vaccines 8, 160. 10.1038/s41541-023-00753-4. PubMed DOI PMC

Agarwal K, Buti M, van Bömmel F, Lampertico P, Janczewska E, Bourliere M, Vanwolleghem T, Lenz O, Verbinnen T, Kakuda TN, Mayer C, Jezorwski J, Muenz D, Beumont M, Kalmeijer R, Biermer M, Lonjon-Domanec I, 2024. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: reef-2. J. Hepatol 81, 404–414. 10.1016/j.jhep.2024.03.046. PubMed DOI

Andrei G, Carter K, Janeba Z, Sampath A, Schang LM, Tarbet EB, Vere Hodge RA, Bray M, Esté JA, 2017. Highlights of the 30th international conference on antiviral research. Antiviral Res 145, 184–196. 10.1016/j.antiviral.2017.07.017. PubMed DOI PMC

Argibay HD, Cardoso CW, de Souza WM, Souza RL, Pellizzaro M, Cunha GM, Clennon J, Weaver SC, Reis MG, Kitron U, Ribeiro GS, 2025. High-resolution spatiotemporal analysis of chikungunya epidemics between 2019 and 2020 in Salvador, Brazil: a municipality-level transmission dynamics study. Lancet Reg. Heal. Am 43, 101003. 10.1016/j.lana.2025.101003. PubMed DOI PMC

Barozi V, Chakraborty S, Govender S, Morgan E, Ramahala R, Graham SC, Bishop NT, Tastan Bishop Ö, 2024. Revealing SARS-CoV-2 Mpro mutation cold and hot spots: dynamic residue network analysis meets machine learning. Comput. Struct. Biotechnol. J 23, 3800–3816. 10.1016/j.csbj.2024.10.031. PubMed DOI PMC

Bekker L-G, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F, PURPOSE 1 Study Team, 2024. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N. Engl. J. Med 391, 1179–1192. 10.1056/NEJMoa2407001. PubMed DOI

Bessiéres M, Roy V, Abuduani T, Favetta P, Snoeck R, Andrei G, Moffat J, Gallardo F, Agrofoglio LA, 2024. Synthesis of LAVR-289, a new [(Z)-3-(acetoxymethyl)-4-(2,4-diaminopyrimidin-6-yl)oxy-but-2-enyl]phosphonic acid prodrug with pronounced antiviral activity against DNA viruses. Eur. J. Med. Chem 271, 116412. 10.1016/j.ejmech.2024.116412. PubMed DOI

Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC, Covid, Moonshot Consortium, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN, 2023. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science 382, eabo7201. 10.1126/science.abo7201. PubMed DOI PMC

Brancale A, Carter K, Delang L, Deval J, Durantel D, Gentry BG, Jordan R, Julander JG, Lo MK, Pérez-Pérez M-JJ, Schang LM, Seley-Radtke KL, Shi P-YY, Vasudevan SG, Whitley RJ, Spengler JR, 2022. Meeting report: 34th international conference on antiviral research. Antivir. Chem. Chemother 30, 20402066221130852. 10.1177/20402066221130853. PubMed DOI PMC

Bray M, Andrei G, Ballana E, Carter K, Durantel D, Gentry B, Janeba Z, Moffat J, Oomen CJ, Tarbet B, Riveira-Muñoz E, Esté JA, International Society for Antiviral Research, 2018. In: Meeting Report: 31st International Conference on Antiviral Research. Antiviral Res, vol. 158, pp. 88–102. 10.1016/j.antiviral.2018.08.002. PubMed DOI PMC

Breugem TI, Riesebosch S, Zhang J, Mykytyn AZ, Krabbendam L, Groen N, Baptista Varela S, Schipper D, van den Doel PB, van Acker R, Stadhouders R, Lamers MM, Haagmans BL, 2025. Variable DPP4 expression in multiciliated cells of the human nasal epithelium as a determinant for MERS-CoV tropism. Proc. Natl. Acad. Sci. U. S. A 122, e2410630122. 10.1073/pnas.2410630122. PubMed DOI PMC

Brouillard M, Mathieu T, Guillot S, Méducin F, Roy V, Marcheteau E, Gallardo F, Caire-Maurisier F, Favetta P, Agrofoglio LA, 2024. Lyotropic liquid crystal emulsions of LAVR-289: influence of internal mesophase structure on cytotoxicity and in-vitro antiviral activity. Int. J. Pharm 665, 124683. 10.1016/j.ijpharm.2024.124683. PubMed DOI

Callaway E, 2020. The coronavirus is mutating - does it matter? Nature 585, 174–177. 10.1038/d41586-020-02544-6. PubMed DOI

Carlin AF, Beadle JR, Ardanuy J, Clark AE, Rhodes V, Garretson AF, Murphy JA, Valiaeva N, Schooley RT, Frieman MB, Hostetler KY, 2024. Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. Antimicrob. Agents Chemother 68, e0103924. 10.1128/aac.01039-24. PubMed DOI PMC

Carlin AF, Beadle JR, Clark AE, Gully KL, Moreira FR, Baric RS, Graham RL, Valiaeva N, Leibel SL, Bray W, McMillan RE, Freshman JE, Garretson AF, McVicar RN, Rana T, Zhang X-Q, Murphy JA, Schooley RT, Hostetler KY, 2023. 1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of oral V2043 in a mouse model of SARS-CoV-2 infection and synthesis and antiviral evaluation of additional phospholipid esters with enhanced anti-SARS-CoV-2 activity. J. Med. Chem 66, 5802–5819. 10.1021/acs.jmedchem.3c00046. PubMed DOI PMC

Carrillo-Bustamante P, Nguyen THT, Oestereich L, Günther S, Guedj J, Graw F, 2017. Determining Ribavirin’s mechanism of action against Lassa virus infection. Sci. Rep 7, 11693. 10.1038/s41598-017-10198-0. PubMed DOI PMC

Celegato M, Sturlese M, Vasconcelos Costa V, Trevisan M, Lallo Dias AS, Souza Passos IB, Queiroz-Junior CM, Messa L, Favaro A, Moro S, Teixeira MM, Loregian A, Mercorelli B, 2023. Small-molecule inhibitor of flaviviral NS3-NS5 interaction with broad-spectrum activity and efficacy in vivo. mBio 14, e0309722. 10.1128/mbio.03097-22. PubMed DOI PMC

Chazot A, Zimberger C, Feracci M, Moussa A, Good S, Sommadossi J-P, Alvarez K, Ferron F, Canard B, 2024. The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolution. PLoS Biol. 22, e3002743. 10.1371/journal.pbio.3002743. PubMed DOI PMC

Chen P, Van Oers TJ, Arutyunova E, Fischer C, Wang C, Lamer T, van Belkum MJ, Young HS, Vederas JC, Lemieux MJ, 2024. A structural comparison of oral SARS-CoV-2 drug candidate ibuzatrelvir complexed with the main protease (Mpro) of SARS-CoV-2 and MERS-CoV. JACS Au 4, 3217–3227. 10.1021/jacsau.4c00508. PubMed DOI PMC

Chen SA, Arutyunova E, Lu J, Khan MB, Rut W, Zmudzinski M, Shahbaz S, Iyyathurai J, Moussa EW, Turner Z, Bai B, Lamer T, Nieman JA, Vederas JC, Julien O, Drag M, Elahi S, Young HS, Lemieux MJ, 2023. SARS-CoV-2 Mpro protease variants of concern display altered viral substrate and cell host target galectin-8 processing but retain sensitivity toward antivirals. ACS Cent. Sci 9, 696–708. 10.1021/acscentsci.3c00054. PubMed DOI PMC

Chilingaryan G, Abelyan N, Sargsyan A, Nazaryan K, Serobian A, Zakaryan H, 2021. Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors. Sci. Rep 11, 11417. 10.1038/s41598-021-91069-7. PubMed DOI PMC

de Lima STS, Hua X, Claro IM, Filho CG, Simões Mello LM, de Jesus R, Bleichrodt A, Maia AMPC, Máximo ACBM, Cavalcante KF, Firmino ACL, Duarte LMF, da Silva LOR, Freitas ARR, Fung IC-H, Chowell G, Lalwani P, Cavalcanti LPG, Romano CM, Proenca-Modena JL, de Souza WM, 2025. Molecular epidemiology of Oropouche virus, ceará state, Brazil, 2024. Emerg. Infect. Dis 31, 838–842. 10.3201/eid3104.241471. PubMed DOI PMC

de Souza WM, de Lima STS, Simões Mello LM, Candido DS, Buss L, Whittaker C, Claro IM, Chandradeva N, Granja F, de Jesus R, Lemos PS, Toledo-Teixeira DA, Barbosa PP, Firmino ACL, Amorim MR, Duarte LMF, Pessoa IB, Forato J, Vasconcelos IL, Maximo ACBM, Araújo ELL, Perdigao Mello L, Sabino EC, Proença-Modena JL, Faria NR, Weaver SC, 2023. Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological study. Lancet Microbe 4, e319–e329. 10.1016/S2666-5247(23)00033-2. PubMed DOI PMC

de Souza WM, Fumagalli MJ, de Lima STS, Parise PL, Carvalho DCM, Hernandez C, de Jesus R, Delafiori J, Candido DS, Carregari VC, Muraro SP, Souza GF, Simões Mello LM, Claro IM, Díaz Y, Kato RB, Trentin LN, Costa CHS, Maximo ACBM, Cavalcante KF, Fiuza TS, Viana VAF, Melo MEL, Ferraz CPM, Silva DB, Duarte LMF, Barbosa PP, Amorim MR, Judice CC, Toledo-Teixeira DA, Ramundo MS, Aguilar PV, Araújo ELL, Costa FTM, Cerqueira-Silva T, Khouri R, Boaventura VS, Figueiredo LTM, Fang R, Moreno B, López-Vergès S, Mello LP, Skaf MS, Catharino RR, Granja F, Martins-de-Souza D, Plante JA, Plante KS, Sabino EC, Diamond MS, Eugenin E, Proença-Mõdena JL, Faria NR, Weaver SC, 2024a. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell Host Microbe 32, 606–622. 10.1016/j.chom.2024.02.011 e8. PubMed DOI PMC

de Souza WM, Ribeiro GS, de Lima STS, de Jesus R, Moreira FRR, Whittaker C, Sallum MAM, Carrington CVF, Sabino EC, Kitron U, Faria NR, Weaver SC, 2024b. Chikungunya: a decade of burden in the Americas. Lancet Reg. Heal. Am 30, 100673. 10.1016/j.lana.2023.100673. PubMed DOI PMC

Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC, HPTN 084 study group, 2022. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet (London, England) 399, 1779–1789. 10.1016/S0140-6736(22)00538-4. PubMed DOI PMC

de Souza WM, Weaver SC, 2024. Effects of climate change and human activities on vector-borne diseases. Nat. Rev. Microbiol 22, 476–491. 10.1038/s41579-024-01026-0. PubMed DOI

DiScipio KA, Weerasooriya S, Szczepaniak R, Hazeen A, Wright LR, Wright DL, Weller SK, 2022. Two-metal ion-dependent enzymes as potential antiviral targets in human herpesviruses. mBio 13, e0322621. 10.1128/mbio.03226-21. PubMed DOI PMC

Dsouza L, Pant A, Offei S, Priyamvada L, Pope B, Satheshkumar PS, Wang Z, Yang Z, 2023. Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts. Antiviral Res 216, 105651. 10.1016/j.antiviral.2023.105651. PubMed DOI PMC

Edwards TC, Lomonosova E, Patel JA, Li Q, Villa JA, Gupta AK, Morrison LA, Bailly F, Cotelle P, Giannakopoulou E, Zoidis G, Tavis JE, 2017. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Res. 143, 205–217. 10.1016/j.antiviral.2017.04.012. PubMed DOI PMC

Edwards TC, Mani N, Dorsey B, Kakarla R, Rijnbrand R, Sofia MJ, Tavis JE, 2019. Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors. Antiviral Res 164, 70–80. 10.1016/j.antiviral.2019.02.005. PubMed DOI PMC

Erameh CO, Koch T, Edeawe OI, Oestereich L, Omansen T, Jochum J, Adomeh DI, Ikponmwonsa O, Aire C, Pahlmann M, Asogun DA, Ogbaini-Emovon E, Okogbenin SA, Günther S, Ramharter M, Akideno PE, Kreuels B, 2023. Focussed Assessment with Sonography in acute Lassa Fever (FASLa): development of a point-of-care protocol and description of common ultrasound findings. J. Infect 87, 27–33. 10.1016/j.jinf.2023.04.008. PubMed DOI

Fanning GC, Zoulim F, Hou J, Bertoletti A, 2019. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug Discov 18, 827–844. 10.1038/s41573-019-0037-0. PubMed DOI

Gaetani M, Sabatier P, Saei AA, Beusch CM, Yang Z, Lundström SL, Zubarev RA, 2019. Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution. J. Proteome Res 18, 4027–4037. 10.1021/acs.jproteome.9b00500. PubMed DOI

Gao Z, Zhang X, Zhang L, Wu S, Ma J, Wang F, Zhou Y, Dai X, Bullitt E, Du Y, Guo J-T, Chang J, 2022. A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response. PLoS Pathog. 18, e1010271. 10.1371/journal.ppat.1010271. PubMed DOI PMC

Garcia AD, Moss B, 2001. Repression of vaccinia virus Holliday junction resolvase inhibits processing of viral DNA into unit-length genomes. J. Virol 75, 6460–6471. 10.1128/JVI.75.14.6460-6471.2001. PubMed DOI PMC

Geneva: Joint United Nations Programme on HIV/AIDS, 2022. In: DANGER: UNAIDS Global AIDS; Update 2022.

Goethals O, Kaptein SJF, Kesteleyn B, Bonfanti J-F, Van Wesenbeeck L, Bardiot D, Verschoor EJ, Verstrepen BE, Fagrouch Z, Putnak JR, Kiemel D, Ackaert O, Straetemans R, Lachau-Durand S, Geluykens P, Crabbe M, Thys K, Stoops B, Lenz O, Tambuyzer L, De Meyer S, Dallmeier K, McCracken MK, Gromowski GD, Rutvisuttinunt W, Jarman RG, Karasavvas N, Touret F, Querat G, de Lamballerie X, Chatel-Chaix L, Milligan GN, Beasley DWC, Bourne N, Barrett ADT, Marchand A, Jonckers THM, Raboisson P, Simmen K, Chaltin P, Bartenschlager R, Bogers WM, Neyts J, Van Loock M, 2023. Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates. Nature 615, 678–686. 10.1038/s41586-023-05790-6. PubMed DOI PMC

Gotchev D, Chen S, Dugan B, Dorsey BD, Wang X, Sheraz M, Kowalski R, Liu F, Tang S, Chiu T, Harasym T, Graves IE, Thi EP, Mason JD, Overholt N, Dugyala R, Lam AM, Cole AG, Sofia MJ, 2024a. Structure-activity relationships and discovery of (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2’,1’:2,3]imidazo[4,5-h]quinoline-3-carboxylic acid (AB-161), a novel orally available and liver-centric HBV RNA destabilize. J. Med. Chem 67, 20467–20494. 10.1021/acs.jmedchem.4c01928. PubMed DOI

Gotchev D, Dorsey BD, Nguyen D, Kakarla R, Dugan B, Chen S, Gao M, Bailey L, Liu F, Harasym T, Chiu T, Tang S, Lee AC-H, Cole AG, Sofia MJ, 2024b. Structure-activity relationships and discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2-h][1,7] naphthyridine-9-carboxylic acid (AB-452), a novel orally available HBV RNA destabilizer. J. Med. Chem 67, 1421–1446. 10.1021/acs.jmedchem.3c01981. PubMed DOI

Gowen BB, Hickerson BT, York J, Westover JB, Sefing EJ, Bailey KW, Wandersee L, Nunberg JH, 2021. Second-generation live-attenuated Candid#1 vaccine virus resists reversion and protects against lethal Junín virus infection in Guinea pigs. J. Virol 95, e0039721. 10.1128/JVI.00397-21. PubMed DOI PMC

Griffen EJ, Boulet P, ASAP Discovery Center, COVID Moonshot, 2024. Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements. Wellcome open Res 9, 374. 10.12688/wellcomeopenres.22645.1. PubMed DOI PMC

Groger M, Akhideno P, Kleist CJ, Babatunde FO, Edeawe O, Hinzmann J, Akhigbe T, Nwatuzor J, Eifediyi G, Müller J, Hinrichs M, Pahlmann M, Sarpong FN, Wagner C, Thielebein A, Aihonwalan L, Koch T, Riedner M, Ogbaini-Emovon E, Okogbenin S, Günther S, Wicha SG, Ramharter M, Oestereich L, Duraffour S, Erameh C, 2023. Pharmacokinetics of ribavirin in the treatment of Lassa fever: an observational clinical study at the Irrua specialist teaching hospital, edo state, Nigeria. Clin. Infect. Dis 76, e841–e848. 10.1093/cid/ciac578. PubMed DOI PMC

Guo F, Wu S, Julander J, Ma J, Zhang X, Kulp J, Cuconati A, Block TM, Du Y, Guo J-T, Chang J, 2016. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J. Virol 90, 10774–10788. 10.1128/JVI.01253-16. PubMed DOI PMC

Horowitz JA, Wasco W, Leiser M, Orr GA, 1988. Interaction of the regulatory subunit of a type II cAMP-dependent protein kinase with mammalian sperm flagellum. J. Biol. Chem 263, 2098–2104. PubMed

Hosmillo M, Lu J, McAllaster MR, Eaglesham JB, Wang X, Emmott E, Domingues P, Chaudhry Y, Fitzmaurice TJ, Tung MK, Panas MD, McInerney G, Locker N, Wilen CB, Goodfellow IG, 2019. Noroviruses subvert the core stress granule component G3BP1 to promote viral VPg-dependent translation. eLife 8. 10.7554/eLife.46681. PubMed DOI PMC

Hu Y, Cheng X, Cao F, Huang A, Tavis JE, 2013. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res 99, 221–229. 10.1016/j.antiviral.2013.06.007. PubMed DOI

Hwang N, Clement JA, Guo J-T, Du Y, 2023. The HBV capsid modulators derived from sulfamoylbenzamides and benzamides: an overview of the progress of patents. Med. Chem. Res 32, 1345–1368. 10.1007/s00044-023-03095-x. DOI

Izmailyan R, Matevosyan M, Khachatryan H, Shavina A, Gevorgyan S, Ghazaryan A, Tirosyan I, Gabrielyan Y, Ayvazyan M, Martirosyan B, Harutyunyan V, Zakaryan H, 2024. Discovery of new antiviral agents through artificial intelligence: in vitro and in vivo results. Antiviral Res 222, 105818. 10.1016/j.antiviral.2024.105818. PubMed DOI

Jones ST, Cagno V, Janeček M, Ortiz D, Gasilova N, Piret J, Gasbarri M, Constant DA, Han Y, Vukovíc L, Král P, Kaiser L, Huang S, Constant S, Kirkegaard K, Boivin G, Stellacci F, Tapparel C, 2020. Modified cyclodextrins as broad-spectrum antivirals. Sci. Adv 6, eaax9318. 10.1126/sciadv.aax9318. PubMed DOI PMC

Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O, PURPOSE 2 Study Team, 2025. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N. Engl. J. Med 392, 1261–1276. 10.1056/NEJMoa2411858. PubMed DOI

Kinganda-Lusamaki E, Amuri-Aziza A, Fernandez-Nuñez N, Makangara-Cigolo J-C, Pratt C, Vakaniaki EH, Hoff NA, Luakanda-Ndelemo G, Akil-Bandali P, Nundu SS, Mulopo-Mukanya N, Ngimba M, Modadra-Madakpa B, Diavita R, Paku-Tshambu P, Pukuta-Simbu E, Merritt S, O’Toole Á, Low N, Nkuba-Ndaye A, Kavunga-Membo H, Shongo Lushima R, Liesenborghs L, Wawina-Bokalanga T, Vercauteren K, Mukadi-Bamuleka D, Subissi L, Muyembe-Tamfum J-J, Kindrachuk J, Ayouba A, Rambaut A, Delaporte E, Tessema S, D’Ortenzio E, Rimoin AW, Hensley LE, Mbala-Kingebeni P, Peeters M, Ahuka-Mundeke S, 2025. Clade I mpox virus genomic diversity in the Democratic Republic of the Congo, 2018-2024: predominance of zoonotic transmission. Cell 188, 4–14.e6. 10.1016/j.cell.2024.10.017. PubMed DOI

Kocabiyik O, Cagno V, Silva PJ, Zhu Y, Sedano L, Bhide Y, Mettier J, Medaglia C, Da Costa B, Constant S, Huang S, Kaiser L, Hinrichs WLJ, Huckriede A, Le Goffic R, Tapparel C, Stellacci F, 2021. Non-toxic virucidal macromolecules show high efficacy against influenza virus ex vivo and in vivo. Adv. Sci. (Weinheim, Baden-Wurttemberg, Ger 8, 2001012. 10.1002/advs.202001012. PubMed DOI PMC

Lam AM, Dugyala RR, Sheraz M, Liu F, Thi EP, Graves IE, Cuconati A, Steuer HM, Ardzinski A, Overholt N, Mason JD, Gotchev D, Cole AG, Harasym TO, Sofia MJ, 2024. Preclinical antiviral and safety profiling of the HBV RNA destabilizer AB-161. Viruses 16. 10.3390/v16030323. PubMed DOI PMC

Lan S, Neilsen G, Slack RL, Cantara WA, Castaner AE, Lorson ZC, Lulkin N, Zhang H, Lee J, Cilento ME, Tedbury PR, Sarafianos SG, 2023. Nirmatrelvir resistance in SARS-CoV-2 omicron_BA.1 and WA1 replicons and escape strategies. bioRxiv Prepr. Serv. Biol 10.1101/2022.12.31.522389. DOI

Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team, 2021. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med 385, 595–608. 10.1056/NEJMoa2101016. PubMed DOI PMC

Langendries L, Jacobs S, Abdelnabi R, Verwimp S, Kaptein S, Baatsen P, Van Mellaert L, Delang L, 2022. Perturbation of alphavirus and flavivirus infectivity by components of the bacterial cell wall. J. Virol 96, e0006022. 10.1128/jvi.00060-22. PubMed DOI PMC

Laporte M, Jochmans D, Bardiot D, Desmarets L, Debski-Antoniak OJ, Mizzon G, Abdelnabi R, Leyssen P, Chiu W, Zhang Z, Nomura N, Boland S, Ohto U, Stahl Y, Wuyts J, De Jonghe S, Stevaert A, van Hemert MJ, Bontes BW, Wanningen P, Groenewold GJM, Zegar A, Owczarek K, Joshi S, Koukni M, Arzel P, Klaassen H, Vanherck J-C, Vandecaetsbeek I, Cremers N, Donckers K, Francken T, Van Buyten T, Rymenants J, Schepers J, Pyrc K, Hilgenfeld R, Dubuisson J, Bosch B-J, Van Kuppeveld F, Eydoux C, Decroly E, Canard B, Naesens L, Weynand B, Snijder EJ, Belouzard S, Shimizu T, Bartenschlager R, Hurdiss DL, Marchand A, Chaltin P, Neyts J, 2025. A coronavirus assembly inhibitor that targets the viral membrane protein. Nature 640, 514–523. 10.1038/s41586-025-08773-x. PubMed DOI PMC

Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, Widen SG, An Z, Weaver SC, Menachery VD, Xie X, Shi P-Y, 2022a. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 39, 110829. 10.1016/j.celrep.2022.110829. PubMed DOI PMC

Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, Ku Z, An Z, Scharton D, Schindewolf C, Widen SG, Menachery VD, Shi P-Y, Weaver SC, 2022b. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294–299. 10.1038/s41586-021-04245-0. PubMed DOI PMC

Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, Kalveram B, Bukreyev A, Ren P, Wang T, Menachery VD, Plante KS, Xie X, Weaver SC, Shi P-Y, 2022c. Publisher Correction: a live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat. Commun 13, 4337. 10.1038/s41467-022-33878-6. PubMed DOI PMC

Lo MK, Shrivastava-Ranjan P, Chatterjee P, Flint M, Beadle JR, Valiaeva N, Murphy J, Schooley RT, Hostetler KY, Montgomery JM, Spiropoulou CF, 2021. Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524). Microbiol. Spectr 9, e0153721. 10.1128/Spectrum.01537-21. PubMed DOI PMC

Malet H, Williams HM, Cusack S, Rosenthal M, 2023. The mechanism of genome replication and transcription in bunyaviruses. PLoS Pathog. 19, e1011060. 10.1371/journal.ppat.1011060. PubMed DOI PMC

Mathieu C, Touret F, Jacquemin C, Janin YL, Nougairéde A, Brailly M, Mazelier M, Décimo D, Vasseur V, Hans A, Valle-Casuso J-C, de Lamballerie X, Horvat B, André P, Si-Tahar M, Lotteau V, Vidalain P-O, 2021. A bioluminescent 3CLPro activity assay to monitor SARS-CoV-2 replication and identify inhibitors. Viruses 13, 1814. 10.3390/v13091814. PubMed DOI PMC

Mayer KH, Molina J-M, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB, 2020. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet (London, England) 396, 239–254. 10.1016/S0140-6736(20)31065-5. PubMed DOI PMC

McMillan RE, Lo MK, Zhang X-Q, Beadle JR, Valiaeva N, Garretson AF, Clark AE, Freshman JE, Murphy J, Montgomery JM, Spiropoulou CF, Schooley RT, Hostetler KY, Carlin AF, 2023. Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs. Antiviral Res 219, 105718. 10.1016/j.antiviral.2023.105718. PubMed DOI PMC

Meier K, Thorkelsson SR, Durieux Trouilleton Q, Vogel D, Yu D, Kosinski J, Cusack S, Malet H, Grünewald K, Quemin ERJ, Rosenthal M, 2023. Structural and functional characterization of the Sin Nombre virus L protein. PLoS Pathog. 19, e1011533. 10.1371/journal.ppat.1011533. PubMed DOI PMC

Moquin SA, Simon O, Karuna R, Lakshminarayana SB, Yokokawa F, Wang F, Saravanan C, Zhang J, Day CW, Chan K, Wang Q-Y, Lu S, Dong H, Wan KF, Lim SP, Liu W, Seh CC, Chen Y-L, Xu H, Barkan DT, Kounde CS, Sim WLS, Wang G, Yeo H-Q, Zou B, Chan WL, Ding M, Song J-G, Li M, Osborne C, Blasco F, Sarko C, Beer D, Bonamy GMC, Sasseville VG, Shi P-Y, Diagana TT, Yeung BKS, Gu F, 2021. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci. Transl. Med 13. 10.1126/scitranslmed.abb2181. PubMed DOI

Mueller HCS, Erameh CO, Gelderblom M, Edeawe OI, Akpasubi OG, Ekoyata EU, Aiterebhe UM, Okoeguale J, Guenther S, Oestereich L, Ramharter M, Okogbenin S, Omansen T, 2024. Electroencephalography in emerging viral infections: lessons learned from implementing an EEG unit in a Lassa fever isolation ward in Nigeria. PLoS Negl. Trop. Dis 18, e0012522. 10.1371/journal.pntd.0012522. PubMed DOI PMC

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi P-Y, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU, 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593. 10.1038/s41586-020-2639-4. PubMed DOI

Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi P-Y, 2020. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun 11, 4059. 10.1038/s41467-020-17892-0. PubMed DOI PMC

Nassal M, 2015. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64, 1972–1984. 10.1136/gutjnl-2015-309809. PubMed DOI

Neilsen G, Lan S, Slack RL, Lorson ZC, Emanuelli Castaner A, Lee R, Edwards KG, Zhang H, Lee J, Cantara WA, Cilento ME, Zhang H, De R, Amblard F, Tedbury PR, Kirby KA, Schinazi RF, Sarafianos SG, 2025. Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease. Sci. Adv 11 (23), eadv8875. 10.1126/sciadv.adv8875. PubMed DOI PMC

Oestereich L, Lüdtke A, Ruibal P, Pallasch E, Kerber R, Rieger T, Wurr S, Bockholt S, Pérez-Girón JV, Krasemann S, Günther S, Muñoz-Fontela C, 2016a. Chimeric mice with competent hematopoietic immunity reproduce key features of severe Lassa fever. PLoS Pathog. 12, e1005656. 10.1371/journal.ppat.1005656. PubMed DOI PMC

Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Muñoz-Fontela C, Gunther S, Ludtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Munoz-Fontela C, Gunther S, Lüdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Muñoz-Fontela C, Günther S, 2016b. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J. Infect. Dis 213, 934–938. 10.1093/infdis/jiv522. PubMed DOI PMC

Okogbenin S, Erameh C, Okoeguale J, Edeawe O, Ekuaze E, Iraoyah K, Agho J, Groger M, Kreuels B, Oestereich L, Babatunde FO, Akhideno P, Günther S, Ramharter M, Omansen T, 2022. Two cases of Lassa fever successfully treated with ribavirin and adjunct dexamethasone for concomitant infections. Emerg. Infect. Dis 28, 2060–2063. 10.3201/eid2810.220625. PubMed DOI PMC

Osawa T, Aoki M, Ehara H, Sekine S-I, 2023. Structures of dengue virus RNA replicase complexes. Mol. Cell 83, 2781–2791.e4. 10.1016/j.molcel.2023.06.023. PubMed DOI

Otsuka Y, Kim E, Krueger A, Shumate J, Wang C, Bdiri B, Ullah S, Park H, Scampavia L, Bannister TD, Chung D, Spicer TP, 2024. High throughput screening for SARS-CoV-2 helicase inhibitors. SLAS Discov. Adv. life Sci. R D 29, 100180. 10.1016/j.slasd.2024.100180. PubMed DOI PMC

Peiris M, Perlman S, 2022. Unresolved questions in the zoonotic transmission of MERS. Curr. Opin. Virol 52, 258–264. 10.1016/j.coviro.2021.12.013. PubMed DOI PMC

Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi P-Y, 2020. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. bioRxiv Prepr. Serv. Biol 10.1101/2020.09.01.278689. DOI

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim S-G, Lu F, Penicaud MC, Tavis JE, Thimme R, Members of the ICE-HBV Working Groups, ICE-HBV Stakeholders Group Chairs, ICE-HBV Senior Advisors Zoulim F, 2019. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol 4, 545–558. 10.1016/S2468-1253(19)30119-0. PubMed DOI PMC

Rosales-Rosas AL, Goossens S, Chiu W, Majumder A, Soto A, Masyn S, Stoops B, Wang L, Kaptein SJF, Goethals O, Delang L, 2024a. The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding. Sci. Adv 10, eadr8338. 10.1126/sciadv.adr8338. PubMed DOI PMC

Rosales-Rosas AL, Soto A, Wang L, Mols R, Fontaine A, Sanon A, Augustijns P, Delang L, 2024b. β-D-N4-hydroxycytidine (NHC, EIDD-1931) inhibits chikungunya virus replication in mosquito cells and ex vivo Aedes aegypti guts, but not when ingested during blood-feeding. Antiviral Res 225, 105858. 10.1016/j.antiviral.2024.105858. PubMed DOI

Rosales-Rosas AL, Wang L, Goossens S, Cuvry A, Li L-H, Santos-Ferreira N, Soto A, Dallmeier K, Rocha-Pereira J, Delang L, 2023. Ex vivo gut cultures of Aedes aegypti are efficiently infected by mosquito-borne alpha- and flaviviruses. Microbiol. Spectr 11, e0519522. 10.1128/spectrum.05195-22. PubMed DOI PMC

Rust BJ, Kean LS, Colonna L, Brandenstein KE, Poole NH, Obenza W, Enstrom MR, Maldini CR, Ellis GI, Fennessey CM, Huang M-L, Keele BF, Jerome KR, Riley JL, Kiem H-P, Peterson CW, 2020. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. Blood 136, 1722–1734. 10.1182/blood.2020006372. PubMed DOI PMC

Sacramento CQ, Bott R, Huang Q, Eaton B, Postnikova E, Sabir AJ, Argade MD, Ratia K, Anantpadma M, Carlier PR, Ly H, Liang Y, Rong L, 2025. Recombinant Pichinde reporter virus as a safe and suitable surrogate for high-throughput antiviral screening against highly pathogenic arenaviruses. Antiviral Res 236, 106117. 10.1016/j.antiviral.2025.106117. PubMed DOI

Salam AP, Cheng V, Edwards T, Olliaro P, Sterne J, Horby P, 2021. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl. Trop. Dis 15, e0009522. 10.1371/journal.pntd.0009522. PubMed DOI PMC

Scachetti GC, Forato J, Claro IM, Hua X, Salgado BB, Vieira A, Simeoni CL, Barbosa ARC, Rosa IL, de Souza GF, Fernandes LCN, de Sena ACH, Oliveira SC, Singh CML, de Lima STS, de Jesus R, Costa MA, Kato RB, Rocha JF, Santos LC, Rodrigues JT, Cunha MP, Sabino EC, Faria NR, Weaver SC, Romano CM, Lalwani P, Proenca-Modena JL, de Souza WM, 2025. Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study. Lancet Infect. Dis 25, 166–175. 10.1016/S1473-3099(24)00619-4. PubMed DOI PMC

Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang X-Q, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY, 2021. Rethinking remdesivir: synthesis, antiviral activity, and pharmacokinetics of oral lipid prodrugs. Antimicrob. Agents Chemother 65, e0115521. 10.1128/AAC.01155-21. PubMed DOI PMC

Shahriar I, Kamra M, Kanduluru AK, Campbell CL, Nguyen TH, Srinivasarao M, Low PS, 2024. Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections. Proc. Natl. Acad. Sci. U. S. A 121, e2408469121. 10.1073/pnas.2408469121. PubMed DOI PMC

Song B-H, Frank JC, Yun S-I, Julander JG, Mason JB, Polejaeva IA, Davies CJ, White KL, Dai X, Lee Y-M, 2024. Comparison of three chimeric Zika vaccine prototypes developed on the genetic background of the clinically proven live-attenuated Japanese encephalitis vaccine SA14-14-2. Int. J. Mol. Sci 26, 195. 10.3390/ijms26010195. PubMed DOI PMC

Spengler JR, Carter K, Delang L, Durantel D, Gowen BB, Herrero LJ, Hurst B, Janeba Z, Jordan R, Luo D, Meier C, Moffat J, Rocha-Pereira J, Seley-Radtke KL, Welch SR, Schang LM, 2023. Meeting report: 36th international conference on antiviral research in Lyon, France - March 13-17, 2023. Antiviral Res 217, 105678. 10.1016/j.antiviral.2023.105678. PubMed DOI PMC

Spengler JR, Welch SR, Deval J, Gentry BG, Brancale A, Carter K, Moffat J, Meier C, Seley-Radtke KL, Schang LM, 2022. Meeting report: 35th international conference on antiviral research in Seattle, Washington, USA - March 21-25, 2022. Antiviral Res 211, 105521. 10.1016/j.antiviral.2022.105521. PubMed DOI PMC

Strampe J, Asogun DA, Speranza E, Pahlmann M, Soucy A, Bockholt S, Pallasch E, Becker-Ziaja B, Duraffour S, Bhadelia N, Ighodalo Y, Oyakhilome J, Omomoh EO, Olokor T, Adomeh DI, Ikponwonsa O, Aire C, Tobin E, Akpede N, Okokhere PO, Okogbenin SA, Akpede GO, Muñoz-Fontela C, Ogbaini-Emovon E, Günther S, Connor JH, Oestereich L, 2021. Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. Lancet Infect. Dis 21, 876–886. 10.1016/S1473-3099(20)30737-4. PubMed DOI PMC

Tajwar R, Bradley DP, Ponzar NL, Tavis JE, 2022. Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein fold. Protein Sci. 31, e4421. 10.1002/pro.4421. PubMed DOI PMC

Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG, 2013. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 9, e1003125. 10.1371/journal.ppat.1003125. PubMed DOI PMC

Tay MYF, Saw WG, Zhao Y, Chan KWK, Singh D, Chong Y, Forwood JK, Ooi EE, Grüber G, Lescar J, Luo D, Vasudevan SG, 2015. The C-terminal 50 amino acid residues of dengue NS3 protein are important for NS3-NS5 interaction and viral replication. J. Biol. Chem 290, 2379–2394. 10.1074/jbc.M114.607341. PubMed DOI PMC

Tramontano E, Tarbet B, Spengler JR, Seley-Radtke K, Meier C, Jordan R, Janeba Z, Gowen B, Gentry B, Esté JA, Bray M, Andrei G, Schang LM, International Society for Antiviral Research, 2019. In: Meeting Report: 32nd International Conference on Antiviral Research. Antiviral Res, vol. 169, 104550. 10.1016/j.antiviral.2019.104550. PubMed DOI PMC

Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O’Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, Amuri-Aziza A, Malyamungu-Bubala N, Mweshi-Kumbana F, Mutimbwa-Mambo L, Belesi-Siangoli F, Mujula Y, Parker E, Muswamba-Kayembe P-C, Nundu SS, Lushima RS, Makangara-Cigolo J-C, Mulopo-Mukanya N, Pukuta-Simbu E, Akil-Bandali P, Kavunga H, Abdramane O, Brosius I, Bangwen E, Vercauteren K, Sam-Agudu NA, Mills EJ, Tshiani-Mbaya O, Hoff NA, Rimoin AW, Hensley LE, Kindrachuk J, Baxter C, de Oliveira T, Ayouba A, Peeters M, Delaporte E, Ahuka-Mundeke S, Mohr EL, Sullivan NJ, Muyembe-Tamfum J-J, Nachega JB, Rambaut A, Liesenborghs L, Mbala-Kingebeni P, 2024. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat. Med 30, 2791–2795. 10.1038/s41591-024-03130-3. PubMed DOI PMC

Van Damme E, Abeywickrema P, Yin Y, Xie J, Jacobs S, Mann MK, Doijen J, Miller R, Piassek M, Marsili S, Subramanian M, Gottlieb L, Abdelnabi R, Van Gool M, Van den Broeck N, De Pauw I, Diels A, Vermeulen P, Temmerman K, Scobey T, Mattocks M, Schäfer A, Jochmans D, De Jonghe S, Leyssen P, Chiu W, Diosa Toro M, Zwaagstra M, Leijs AA, De Gruyter HLM, Buyck C, Van Den Heede K, Jacobs F, Van den Eynde C, Thijs L, Raeymaekers V, Miller S, Del Rosario A, Neyts J, Peeters D, Baric RS, van Kuppeveld FJM, Snijder EJ, van Hemert MJ, Monshouwer M, Sharma S, Draghia-Akli R, Koul A, Van Loock M, 2025. A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein. Nature 640, 506–513. 10.1038/s41586-025-08651-6. PubMed DOI PMC

Vendeville S, Amblard F, Bassit L, Beigelman LN, Blatt LM, Chen X, Chou L, Kum DB, Chanda S, Deval J, Geng X, Gupta K, Jekle A, Hu H, Hu X, Kang H, Liu C, Liu J, McGowan DC, Misner DL, Raboisson P, Sanchez AA, Serebryany V, Stoycheva AD, Symons JA, Tan H, Vanrusselt H, Williams C, Welch M, Zhang L, Zhang Q, Zhang Y, Schinazi RF, Smith DB, Debing Y, 2024. The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075. J. Med. Chem 67, 21126–21142. 10.1021/acs.jmedchem.4c01814. PubMed DOI

Vere Hodge A, 2011. Scientific report: highlights of 24th ICAR, 8-11 may 2011, sofia, Bulgaria. Antivir. Chem. Chemother 22, 75–85. 10.3851/IMP1885. PubMed DOI

Vere Hodge A, 2003a. Antiviral research–16th annual international conference. Satellite symposium: clinical update on antiviral drugs. 27 april-1 may 2003, savannah, ga, USA. Idrugs 6, 515–517. PubMed

Vere Hodge A, 2003b. Antiviral research–16th international conference: 27 april-1 may 2003. Savannah, GA, USA Idrugs 6, 512–514. PubMed

Vere Hodge RA, 2017. Meeting report: 29th international conference on antiviral research in La jolla, CA, USA. Antiviral Res 137, 23–40. 10.1016/j.antiviral.2016.10.014. PubMed DOI PMC

Vere Hodge RA, 2015. Meeting report: 28th international conference on antiviral research in Rome, Italy. Antiviral Res 123, 172–187. 10.1016/j.antiviral.2015.09.015. PubMed DOI PMC

Vere Hodge RA, 2014. Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA. Antiviral Res 111, 143–153. 10.1016/j.antiviral.2014.08.009. PubMed DOI PMC

Vere Hodge RA, 2013. Meeting report: 26th international conference on antiviral research. Antiviral Res 100, 276–285. 10.1016/j.antiviral.2013.08.006. PubMed DOI PMC

Viswanathan U, Mani N, Hu Z, Ban H, Du Y, Hu J, Chang J, Guo J-T, 2020. Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B. Antiviral Res. 182, 104917. 10.1016/j.antiviral.2020.104917. PubMed DOI PMC

Wang L, Zhu Q, Zhang JD, Zhang Y, Ni X, Xiang K, Jiang J, Li B, Yu Y, Hu H, Zhang M, Wu W, Zeng J, Yan Z, Dai J, Sun K, Zhang X, Chen D, Feng S, Sach-Peltason L, Young JAT, Gao L, 2023. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J. Hepatol 78, 742–753. 10.1016/j.jhep.2022.12.014. PubMed DOI

Wang Y, Sun L, Fernandes L, Wang Y-H, Zou J, Franklin SJ, Hu Y, Palmer LK, Yeung J, Barriga D, Russell WK, Moquin SA, Shi P-Y, Skepper C, Xie X, 2025. Mechanistic insights into dengue virus inhibition by a clinical trial compound NITD-688. Proc. Natl. Acad. Sci. U. S. A 122, e2426922122. 10.1073/pnas.2426922122. PubMed DOI PMC

Watanabe S, Vasudevan SG, 2014. Evaluation of dengue antiviral candidates in vivo in mouse model. Methods Mol. Biol 1138, 391–400. 10.1007/978-1-4939-0348-1_24. PubMed DOI

Wawina-Bokalanga T, Merritt S, Kinganda-Lusamaki E, Jansen D, Halbrook M, Pukuta-Simbu E, O’Toole Á, Hasivirwe Vakaniaki E, Ola-Mpumbe R, Kwete-Mbokama P, Akil-Bandali P, Kacita C, Ponga-Museme A, Mapenzi-Kashali N, Amuri-Aziza A, Tshiani-Mbaya O, Paku-Tshambu P, Dantas PH, de Block T, Lokilo E, Muswamba C, Makangara-Cigolo J-C, Luakanda G, Ngandu C, Kelvin DJ, Pratt C, Ayouba A, Tessema S, Ndembi N, Rezende AM, Delaporte E, Mwamba D, Subissi L, Liesenborghs L, Hoff NA, Peeters M, Low N, Ahuka-Mundeke S, Muyembe-Tamfum J-J, Rimoin AW, Kindrachuk J, Vercauteren K, Rambaut A, Mbala-Kingebeni P, 2024. Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox Outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for Increasingly Sustained Human-To-Human Transmission of Subclade Ia. 10.1101/2024.11.15.24317404. DOI

Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier R-C, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P, 2024. Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial. J. Hepatol 81, 621–629. 10.1016/j.jhep.2024.05.001. PubMed DOI

Welch SR, Bilello JP, Carter K, Delang L, Dirr L, Durantel D, Feng JY, Gowen BB, Herrero LJ, Janeba Z, Kleymann G, Lee AA, Meier C, Moffat J, Schang LM, Schiffer JT, Seley-Radtke KL, Sheahan TP, Spengler JR, 2024. Meeting report of the 37th international conference on antiviral research in Gold Coast, Australia, may 20-24, 2024, organized by the international society for antiviral research. Antiviral Res 232, 106037. 10.1016/j.antiviral.2024.106037. PubMed DOI PMC

Widagdo W, Okba NMA, Li W, de Jong A, de Swart RL, Begeman L, van den Brand JMA, Bosch B-J, Haagmans BL, 2019. Species-specific colocalization of Middle East respiratory syndrome coronavirus attachment and entry receptors. J. Virol 93. 10.1128/JVI.00107-19. PubMed DOI PMC

Widagdo W, Raj VS, Schipper D, Kolijn K, van Leenders GJLH, Bosch BJ, Bensaid A, Segalés J, Baumgärtner W, Osterhaus ADME, Koopmans MP, van den Brand JMA, Haagmans BL, 2016. Differential expression of the Middle East respiratory syndrome coronavirus receptor in the upper respiratory tracts of humans and dromedary camels. J. Virol 90, 4838–4842. 10.1128/JVI.02994-15. PubMed DOI PMC

Williams HM, Thorkelsson SR, Vogel D, Busch C, Milewski M, Cusack S, Grünewald K, Quemin ERJ, Rosenthal M, 2024. Structural snapshots of phenuivirus cap-snatching and transcription. Nucleic Acids Res. 52, 6049–6065. 10.1093/nar/gkae330. PubMed DOI PMC

Williams HM, Thorkelsson SR, Vogel D, Milewski M, Busch C, Cusack S, Grünewald K, Quemin ERJ, Rosenthal M, 2023. Structural insights into viral genome replication by the severe fever with thrombocytopenia syndrome virus L protein. Nucleic Acids Res. 51, 1424–1442. 10.1093/nar/gkac1249. PubMed DOI PMC

Woodson ME, Walden HF, Mottaleb MA, Makri M, Prifti G-M, Moianos D, Pardali V, Zoidis G, Tavis JE, 2025. Efficacy and in vitro pharmacological assessment of novel N-hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors. Antimicrob. Agents Chemother 69, e0145524. 10.1128/aac.01455-24. PubMed DOI PMC

World Health Organization, 2024. Global hepatitis report 2024: action for access in low- and middle-income countries [WWW Document]. URL. https://www.who.int/publications/i/item/9789240091672, 7.7.24.

Wright LR, Wright DL, Weller SK, 2022. Viral nucleases from herpesviruses and coronavirus in recombination and proofreading: potential targets for antiviral drug discovery. Viruses 14. 10.3390/v14071557. PubMed DOI PMC

Xia H, Zou J, Kurhade C, Cai H, Yang Q, Cutler M, Cooper D, Muik A, Jansen KU, Xie X, Swanson KA, Shi P-Y, 2022. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host Microbe 30, 485–488.e3. 10.1016/j.chom.2022.02.015. PubMed DOI PMC

Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE, Aguilar PV, Plante KS, Weaver SC, Makino S, LeDuc JW, Menachery VD, Shi P-Y, 2020a. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841–848.e3. 10.1016/j.chom.2020.04.004. PubMed DOI PMC

Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, Liu J, Ren P, Balakrishnan M, Cihlar T, Tseng C-TK, Makino S, Menachery VD, Bilello JP, Shi P-Y, 2020b. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun 11, 5214. 10.1038/s41467-020-19055-7. PubMed DOI PMC

Xie X, Zou J, Kurhade C, Liu M, Ren P, Shi Pei-Yong, 2022. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine. Cell Rep. 41, 111729. 10.1016/j.celrep.2022.111729. PubMed DOI PMC

Xie X, Zou J, Wang Q-Y, Noble CG, Lescar J, Shi P-Y, 2014. Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus. Virology 450–451, 250–257. 10.1016/j.virol.2013.12.025. PubMed DOI

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W, 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 3. 10.7554/eLife.00049. PubMed DOI

Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, Baum A, Diehl WE, Dauphin A, Carbone C, Veinotte K, Egri SB, Schaffner SF, Lemieux JE, Munro JB, Rafique A, Barve A, Sabeti PC, Kyratsous CA, Dudkina NV, Shen K, Luban J, 2020. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739–751.e8. 10.1016/j.cell.2020.09.032. PubMed DOI PMC

Zellweger RM, Prestwood TR, Shresta S, 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7, 128–139. 10.1016/j.chom.2010.01.004. PubMed DOI PMC

Zhang X, Liu Y, Liu J, Bailey AL, Plante KS, Plante JA, Zou J, Xia H, Bopp NE, Aguilar PV, Ren P, Menachery VD, Diamond MS, Weaver SC, Xie X, Shi P-Y, 2021. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell 184, 2229–2238.e13. 10.1016/j.cell.2021.02.044. PubMed DOI PMC

Zhou NE, Tang S, Bian X, Parai MK, Krieger IV, Flores A, Jaiswal PK, Bam R, Wood JL, Shi Z, Stevens LJ, Scobey T, Diefenbacher MV, Moreira FR, Baric TJ, Acharya A, Shin J, Rathi MM, Wolff KC, Riva L, Bakowski MA, McNamara CW, Catanzaro NJ, Graham RL, Schultz DC, Cherry S, Kawaoka Y, Halfmann PJ, Baric RS, Denison MR, Sheahan TP, Sacchettini JC, 2024. An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo. Cell Rep. 43, 114929. 10.1016/j.celrep.2024.114929. PubMed DOI PMC

Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, Zhang Y, Lee D-Y, Sahin U, Anderson AS, Gruber WC, Xie X, Swanson KA, Shi P-Y, 2023. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N. Engl. J. Med 388, 854–857. 10.1056/NEJMc2214916. PubMed DOI PMC